

Contents

List of Figures	xxix
List of Tables	xxxi
List of Examples	xxxv
List of SAS Macros and R Functions	xxxix
1 Introduction	1
1.1 Motivation	1
1.2 Adaptive Design Methods in Clinical Trials	2
1.2.1 Group Sequential Design	3
1.2.2 Sample-Size Reestimation Design	3
1.2.3 Drop-Loser Design	5
1.2.4 Adaptive Randomization Design	6
1.2.5 Adaptive Dose-Finding Design	6
1.2.6 Biomarker-Adaptive Design	7
1.2.7 Adaptive Treatment-Switching Design	9
1.2.8 Clinical Trial Simulation	10
1.2.9 Regulatory Aspects	10
1.2.10 Characteristics of Adaptive Designs	12
1.3 FAQs about Adaptive Designs	13
1.4 Roadmap	16
2 Classical Design	23
2.1 Overview of Drug Development	23

2.2	Two-Group Superiority and Noninferiority Designs	25
2.2.1	General Approach to Power Calculation	25
2.2.2	Powering Trials Appropriately	29
2.3	Two-Group Equivalence Trial	31
2.3.1	Equivalence Test	31
2.3.2	Average Bioequivalence	34
2.3.3	Population and Individual Bioequivalence	37
2.4	Dose-Response Trials	38
2.4.1	Unified Formulation for Sample-Size	39
2.4.2	Application Examples	41
2.4.3	Determination of Contrast Coefficients	44
2.4.4	SAS Macro for Power and Sample-Size	45
2.5	Summary and Discussion	47
3	Theory of Hypothesis-Based Adaptive Design	53
3.1	Introduction	53
3.2	General Theory	55
3.2.1	Stopping Boundary	55
3.2.2	Formula for Power and Adjusted p -value	56
3.2.3	Selection of Test Statistics	57
3.2.4	Polymorphism	58
3.2.5	Adjusted Point Estimates	59
3.2.6	Derivation of Confidence Intervals	63
3.3	Design Evaluation—Operating Characteristics	64
3.3.1	Stopping Probabilities	64
3.3.2	Expected Duration of an Adaptive Trial	64
3.3.3	Expected Sample Sizes	65
3.3.4	Conditional Power and Futility Index	65
3.3.5	Utility and Decision Theory	66
3.4	Summary	67
4	Method with Direct Combination of p -values	71
4.1	Method Based on Individual p -values	71
4.2	Method Based on the Sum of p -values	76
4.3	Method with Product of p -values	83
4.4	Event-Based Adaptive Design	94
4.5	Adaptive Design for Equivalence Trial	96
4.6	Summary	100
5	Method with Inverse-Normal p -values	103

5.1	Method with Linear Combination of z-Scores	103
5.2	Lehmacher and Wassmer Method	106
5.3	Classical Group Sequential Method	111
5.4	Cui-Hung-Wang Method	114
5.5	Lan-DeMets Method	114
5.5.1	Brownian Motion	115
5.5.2	Lan-DeMets Error-Spending Method	117
5.6	Fisher-Shen Method	120
5.7	Summary	120
6	Adaptive Noninferiority Design with Paired Binary Data	123
6.1	Noninferiority Design	123
6.1.1	Fixed-Margin Method	125
6.1.2	λ -Portion Method	125
6.1.3	Synthesis Method	126
6.2	Noninferiority Design with Fixed-Margin Method for Paired Data	126
6.2.1	Classical Design	126
6.2.2	Adaptive Design	128
6.3	Conditional Power and Sample-Size Reestimation	129
6.4	Type-I Error Control	129
6.5	Prostate Cancer Diagnostic Trial	130
6.5.1	Preliminary Data for Trial Design	130
6.5.2	The Effectiveness Requirements	131
6.5.3	Design for Sensitivity	131
6.5.4	Design for Specificity	132
6.5.5	Summary of Design	134
6.6	Summary	138
7	Adaptive Design with Incomplete Paired Data	141
7.1	Introduction	141
7.2	Mixture of Paired and Unpaired Data	142
7.3	Hypothesis Test	146
7.4	Type-I Error Control and Coverage Probability	146
7.5	Classical Trial Design	147
7.5.1	Power and Sample Size	147
7.5.2	Trial Design Examples	149
7.6	Adaptive Trial Design	151
7.7	Summary	155

8	<i>K</i> -Stage Adaptive Designs	157
8.1	Introduction	157
8.2	Determination of Stopping Boundary	157
8.2.1	Analytical Formulation for MSP	157
8.2.2	Analytical Formulation for MPP	160
8.2.3	Numerical Algorithm For MINP	161
8.3	Monte Carlo Approach	164
8.3.1	Normal Endpoint	164
8.3.2	Binary Endpoint	170
8.3.3	Survival Endpoint	174
8.4	Summary	179
9	Conditional Error Function Method and Conditional Power	183
9.1	Proschan-Hunsberger Method	183
9.2	Denne Method	186
9.3	Müller-Schäfer Method	187
9.4	Extension of Conditional Error Approach	187
9.5	Conditional Power	191
9.6	Adaptive Futility Design	196
9.6.1	Utilization of an Early Futility Boundary	196
9.6.2	Design with a Futility Index	196
9.7	Summary	197
10	Recursive Adaptive Design	199
10.1	<i>p</i> -clud Distribution	199
10.2	Error-Spending and Conditional Error Principles	201
10.3	Recursive Two-Stage Design	203
10.3.1	Sum of Stagewise <i>p</i> -values	204
10.3.2	Product of Stagewise <i>p</i> -values	205
10.3.3	Inverse-Normal Stagewise <i>p</i> -values	206
10.3.4	Application Example	206
10.4	Recursive Combination Tests	209
10.5	Decision Function Method	212
10.6	Summary and Discussion	213
11	Unblinded Sample-Size Reestimation Design	217
11.1	Opportunity	217
11.2	Adaptation Rules	218
11.2.1	Adjustment Based on Effect-Size Ratio	218

11.2.2	Adjustment Based on Conditional Power	219
11.3	Stopping Boundaries for SSR	220
11.4	Basic Considerations in Designing SSR Trial	220
11.5	SAS Macros for Sample-Size Reestimation	225
11.6	Power Comparisons in Promising-Zone	228
11.7	Analysis of Design with Sample-Size Adjustment	233
11.7.1	Adjusted p -value	233
11.7.2	Confidence Interval	234
11.7.3	Adjusted Point Estimates	235
11.8	Trial Examples	236
11.9	Summary and Discussion	240
12	Blinded and Semi-Blinded Sample-Size Reestimation Design	243
12.1	Introduction	243
12.2	Maximum Information Design	244
12.3	Distribution-Informed Design	245
12.3.1	Mean Difference Estimated from Blinded Data . .	245
12.3.2	Mean Difference: Unequal Variance	247
12.3.3	Rate Difference	249
12.3.4	Semi-Blinded Method	249
12.3.5	Simulation Comparison	250
12.4	Operating Characteristics of Sample-Size Reestimation	253
12.5	Mixed-Method for Sample-Size Reestimation Design . . .	258
12.6	Revealing Treatment Difference via Stratified Randomization	260
12.7	Summary	265
13	Adaptive Design with Coprimary Endpoints	267
13.1	Introduction	267
13.2	Group Sequential Design with Multiple Coprimary Endpoints	269
13.3	Stopping Boundaries	270
13.4	Examples of Coprimary Endpoint Design	272
13.5	Simulation of Group Sequential Trial with Coprimary End- points	274
13.6	Conditional Power and Sample Size Reestimation	275
13.7	Summary	280
14	Multiple-Endpoint Adaptive Design	283

14.1	Multiple-Testing Taxonomy	283
14.2	Multiple-Testing Approaches	288
14.2.1	Single-Step Procedures	288
14.2.2	Stepwise Procedures	290
14.2.3	Common Gatekeeper Procedure	295
14.2.4	Tree Gatekeeping Procedure	298
14.3	Multiple-Endpoint Adaptive Design	299
14.3.1	Tang–Geller Method	299
14.3.2	Single Primary with Secondary Endpoints	300
14.4	Summary and Discussion	305
15	Pick-the-Winners Design	307
15.1	Opportunity	307
15.1.1	Impact Overall Alpha Level and Power	307
15.1.2	Reduction in Expected Trial Duration	308
15.1.3	Overview of Multiple-Arm Designs	309
15.2	Pick-the-Winner Design	311
15.3	Adaptive Dunnett Test	315
15.4	Summary and Discussion	317
16	The Add-Arm Design for Unimodal Response	319
16.1	Introduction	319
16.2	The Add-Arm Design	323
16.2.1	Design Description	323
16.2.2	The Interim and Final Test Statistics	325
16.3	Extension of Add-Arm Designs	333
16.3.1	The 5+1 Add-Arm Design	333
16.3.2	The 6+1 Add-Arm Design	335
16.3.3	The 7+1 Add-Arm Design	336
16.4	Comparison of Adaptive Design Methods	338
16.4.1	Threshold c_R and Stopping Boundary c_α	338
16.4.2	Comparison of Seamless Designs	339
16.4.3	Comparisons of Phase-II Dose-Finding Designs	342
16.5	Clinical Trial Examples	343
16.6	Summary	348
17	Biomarker-Enrichment Design	351
17.1	Introduction	351
17.2	Design with Classifier Biomarker	353

17.2.1	Setting the Scene	353
17.2.2	Classical Design with Classifier Biomarker	355
17.2.3	Adaptive Design with Classifier Biomarker	358
17.3	Challenges in Biomarker Validation	362
17.3.1	Classical Design with Biomarker Primary Endpoint	362
17.3.2	Treatment-Biomarker-Endpoint Relationship	362
17.3.3	Multiplicity and False Positive Rate	364
17.3.4	Validation of Biomarkers	365
17.3.5	Biomarkers in Reality	366
17.4	Adaptive Design with Prognostic Biomarkers	366
17.4.1	Optimal Design	366
17.4.2	Prognostic Biomarker in Designing Survival Trial	367
17.5	Adaptive Design with Predictive Marker	368
17.6	Summary and Discussion	368
18	Biomarker-Informed Adaptive Design	371
18.1	Introduction	371
18.2	Motivations and Concepts	372
18.3	Issues in Conventional One-Level Correlation Model	373
18.4	Two-Stage Winner Design	375
18.5	Two-Level Relationship Model for Two-Stage Winner Design	376
18.5.1	Test Statistic and Its Distribution	376
18.5.2	Type-I Error Rate Control	378
18.5.3	Performance Evaluation of Two-Stage Winner Design	379
18.5.4	Parameter Estimation	381
18.6	Hierarchical Model	382
18.7	Summary	385
19	Survival Modeling and Adaptive Treatment Switching	389
19.1	Introduction to Survival Data Modeling	389
19.1.1	Basic Terms in Survival Analysis	389
19.1.2	Maximum Likelihood Method	390
19.1.3	Overview of Survival Model	391
19.2	First-Hitting-Time Model	395
19.2.1	Wiener Process and First Hitting Time	395
19.2.2	Covariates and Link Function	396

19.2.3	Parameter Estimation and Inference	396
19.2.4	Applications of First-Hitting-Time Model	397
19.2.5	Multivariate Model with Biomarkers	398
19.3	Multistage Model	401
19.3.1	General Framework of Multistage Model	401
19.3.2	Covariates and Treatment Switching	403
19.4	Summary and Discussion	405
20	Response-Adaptive Allocation Design	409
20.1	Opportunities	409
20.2	Traditional Randomization Methods	410
20.3	Basic Response-Adaptive Randomizations	411
20.3.1	Play-the-Winner Model	411
20.3.2	Randomized Play-the-Winner Model	412
20.3.3	Optimal Randomized Play-the-Winner	413
20.4	Adaptive Design with Randomized Play-the-Winner	414
20.5	General Response-Adaptive Randomization	418
20.5.1	SAS Macro for K -Arm RAR with Binary Endpoint	418
20.5.2	SAS Macro for K -Arm RAR with Normal Endpoint	420
20.5.3	RAR for General Adaptive Designs	423
20.6	Sequential Parallel Comparison Design	423
20.7	Summary and Discussion	425
21	Introductory Bayesian Approach in Clinical Trial	427
21.1	Introduction	427
21.2	Bayesian Learning Mechanism	428
21.3	Bayesian Basics	429
21.3.1	Bayes' Rule	429
21.3.2	Conjugate Family of Distributions	431
21.4	Trial Design	432
21.4.1	Bayesian for Classical Design	432
21.4.2	Bayesian Power	434
21.4.3	Frequentist Optimization	435
21.4.4	Bayesian Optimal Adaptive Designs	437
21.5	Trial Monitoring	441
21.6	Analysis of Data	442
21.7	Interpretation of Outcomes	444

21.8	Regulatory Perspective	446
21.9	Summary and Discussion	447
22	Adaptive Dose-Escalation Trial	449
22.1	Oncology Dose-Escalation Trial	449
22.1.1	Dose Level Selection	449
22.1.2	Traditional Escalation Rules	450
22.1.3	Simulations Using Traditional Escalation Algorithms	453
22.2	Continual Reassessment Method	455
22.2.1	Probability Model for Dose-Response	456
22.2.2	Prior Distribution of Parameter	456
22.2.3	Reassessment of Parameter	457
22.2.4	Assignment of Next Patient	458
22.2.5	Stopping Rule	458
22.3	Alternative Form CRM	458
22.4	Simulations of CRM	459
22.5	Bayesian Model Averaging CRM	464
22.6	Summary and Discussion	465
23	Bayesian Design for Efficacy–Toxicity Trade-Off and Drug Combination	467
23.1	Introduction	467
23.2	Thall–Russell Independent Model	467
23.3	Efficacy–Toxicity Trade-Off Model	469
23.4	Odds Ratio Trade-off Model	470
23.5	Drug Combination	472
23.6	Summary	474
24	Bayesian Approach to Biosimilarity Trial	477
24.1	Introduction	477
24.2	Dilemma of Frequentist Noninferiority Trial	478
24.3	Synergic Constancy Approach	479
24.3.1	Conditional Bias of Historical Trial Data	479
24.3.2	Requirements for Biosimilarity or Noninferiority	482
24.4	Bayesian Approach Combining Preclinical and Clinical Data	487
24.5	Bayesian Hierarchical Bias Model	490
24.5.1	Biosimilarity Using Composite Endpoint	490

24.5.2	Study Design and Noninferiority Hypotheses . . .	491
24.5.3	Bayesian Approach	492
24.5.4	Hierarchical Bias Model	492
24.6	Summary	497
25	Adaptive Multiregional Trial Design	499
25.1	Introduction	499
25.2	Unified Additional Requirement for Regional Approval in MRCT	501
25.2.1	Current Consistency Study	501
25.2.2	The Unified Regional Requirement	504
25.2.3	Determination of Parameter λ and α_i	507
25.3	Optimal Classical MRCT Design	512
25.3.1	Maximum Power Design	512
25.3.2	Maximum Utility Design	513
25.4	Optimal Adaptive MRCT Design	513
25.5	Bayesian Approach	518
25.6	Practical Issues and Challenges	520
25.7	Summary	521
26	SAS and R Modules for Group Sequential Design	525
26.1	Introduction	525
26.2	SEQDESIGN Procedure	526
26.2.1	PROC SEQDESIGN Statement	526
26.2.2	DESIGN Statement	527
26.2.3	SAMPLESIZE Statement	527
26.3	Examples with Proc SEQDESIGN	530
26.4	SAS SEQTEST and R sgDesign	531
27	Data Analysis of Adaptive Trial	535
27.1	Introduction	535
27.2	p -value Calculation	536
27.3	Parameter Estimation	537
27.4	Confidence Interval	540
27.5	Parameter Estimation in Trials with Arm Selection	542
27.5.1	Parametric Bootstrap Approach	544
27.5.2	Shrinkage Estimators	547
27.5.3	Empirical Bayes Estimators	548
27.6	Summary	550

28	Planning, Execution, Analysis, and Reporting	553
28.1	Validity and Integrity	553
28.2	Study Planning	554
28.3	Working with Regulatory Agency	555
28.4	Trial Monitoring	559
28.5	Analysis and Reporting	560
28.6	Clinical Trial Simulation	561
28.7	Summary	562
29	Debates in Adaptive Designs	565
29.1	My Standing Point	565
29.2	Decision Theory Basics	566
29.3	Evidence Measure	567
29.3.1	Frequentist p -value	568
29.3.2	Bayes Factor	568
29.3.3	Bayesian p -value	569
29.3.4	Repeated Looks	570
29.3.5	Role of Alpha in Drug Development	570
29.4	Statistical Principles	571
29.5	Behaviors of Statistical Principles in Adaptive Designs	575
29.5.1	Sufficiency Principle	575
29.5.2	Minimum Sufficiency Principle and Efficiency	576
29.5.3	Conditionality and Exchangeability Principles	577
29.5.4	Equal Weight Principle	578
29.5.5	Consistency of Trial Results	579
29.5.6	Bayesian Aspects	580
29.5.7	Type-I Error, p -value, Estimation	581
29.5.8	The 0-2-4 Paradox	582
29.6	Summary	583
Appendix A	Random Number Generation	585
A.1	Random Number	585
A.2	Uniformly Distributed Random Number	585
A.3	Inverse CDF Method	586
A.4	Acceptance–Rejection Methods	586
A.5	Multivariate Distribution	587
Appendix B	A Useful Utility	591

Appendix C	SAS Macros for Add-Arm Designs	593
C.1	The 5+1 Add-Arm Design	593
C.2	The 6+1 Add-Arm Design	594
C.3	The 7+1 Add-Arm Design	596
Appendix D	Implementing Adaptive Designs in R	599
Bibliography		611
Index		645